Citadel Advisors’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-100
| Closed | -$404 | – | 12782 |
|
|
2025
Q1 | $404 | Sell |
100
-78,900
| -100% | -$263K | ﹤0.01% | 14272 |
|
|
2024
Q4 | $253K | Sell |
79,000
-84,600
| -52% | -$287K | ﹤0.01% | 10012 |
|
|
2024
Q3 | $366K | Sell |
163,600
-31,300
| -16% | -$72.2K | ﹤0.01% | 8890 |
|
|
2024
Q2 | $419K | Buy |
194,900
+32,400
| +20% | +$57.7K | ﹤0.01% | 8420 |
|
|
2024
Q1 | $333K | Buy |
162,500
+100,100
| +160% | +$200K | ﹤0.01% | 9238 |
|
|
2023
Q4 | $143K | Buy |
62,400
+42,600
| +215% | +$92.8K | ﹤0.01% | 10455 |
|
|
2023
Q3 | $33.7K | Sell |
19,800
-11,000
| -36% | -$25K | ﹤0.01% | 12181 |
|
|
2023
Q2 | $76.1K | Sell |
30,800
-13,160
| -30% | -$35.9K | ﹤0.01% | 11296 |
|
|
2023
Q1 | $98.9K | Buy |
43,960
+14,030
| +47% | +$70.4K | ﹤0.01% | 11279 |
|
|
2022
Q4 | $153K | Buy |
29,930
+5,750
| +24% | +$41.4K | ﹤0.01% | 10583 |
|
|
2022
Q3 | $251K | Sell |
24,180
-980
| -4% | -$11.7K | ﹤0.01% | 9958 |
|
|
2022
Q2 | $259K | Buy |
25,160
+19,870
| +376% | +$260K | ﹤0.01% | 10140 |
|
|
2022
Q1 | $94K | Sell |
5,290
-14,930
| -74% | -$321K | ﹤0.01% | 12344 |
|
|
2021
Q4 | $629K | Sell |
20,220
-990
| -5% | -$32.8K | ﹤0.01% | 9104 |
|
|
2021
Q3 | $700K | Buy |
21,210
+2,160
| +11% | +$63.8K | ﹤0.01% | 9067 |
|
|
2021
Q2 | $562K | Buy |
+19,050
| New | +$528K | ﹤0.01% | 9799 |
|
Citadel Advisors's CKPT Position: Q1 2025 in Review
Citadel Advisors sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 263 shares — an estimated $877 sold.
Citadel Advisors first reported a position in CKPT in Q2 2020 and held it in 14 quarters. The position peaked at $674K in Q3 2021. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.
- Citadel Advisors reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 263 Checkpoint Therapeutics shares in Q1 2025, an estimated $877.
- Citadel Advisors first reported a position in Checkpoint Therapeutics in Q2 2020 and held it in 14 quarters.
- Citadel Advisors's Checkpoint Therapeutics position peaked at $674K in Q3 2021.
- 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.